Kidney Transplant Recipients

Nephrology
4
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Veloxis Pharmaceuticals
2 programs
2
Conversion to extended-release tacrolimusPhase 41 trial
Envarsus XRPhase 41 trial
Active Trials
NCT06751992Not Yet RecruitingEst. Oct 2027
NCT03979365CompletedEst. Mar 2022
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
MizoribinePhase 41 trial
Active Trials
NCT05293704Unknown30Est. May 2024
M&
Merck & Co.RAHWAY, NJ
1 program
1
Varivax®Phase 11 trial
Active Trials
NCT00005009Terminated7Est. Jun 2001
Astellas
AstellasChina - Shenyang
1 program
ATF-Fresenius SN/A1 trial
Active Trials
NCT02392312Completed950Est. Mar 2018
Genomics
GenomicsUK - Oxford
1 program
Validation of Gene Expression Markers of Renal Allograft Functional DeclineN/A1 trial
Active Trials
NCT01782586Completed499Est. Mar 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Veloxis PharmaceuticalsConversion to extended-release tacrolimus
Lee's PharmaceuticalMizoribine
Veloxis PharmaceuticalsEnvarsus XR
Merck & Co.Varivax®
AstellasATF-Fresenius S
GenomicsValidation of Gene Expression Markers of Renal Allograft Functional Decline

Clinical Trials (6)

Total enrollment: 1,486 patients across 6 trials

NCT06751992Veloxis PharmaceuticalsConversion to extended-release tacrolimus

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

Start: Dec 2025Est. completion: Oct 2027
Phase 4Not Yet Recruiting
NCT05293704Lee's PharmaceuticalMizoribine

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

Start: May 2022Est. completion: May 202430 patients
Phase 4Unknown
NCT03979365Veloxis PharmaceuticalsEnvarsus XR

Envarsus XR Compared to Immediate Release Tacrolimus

Start: Jul 2019Est. completion: Mar 2022
Phase 4Completed
NCT00005009Merck & Co.Varivax®

Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Start: Feb 1998Est. completion: Jun 20017 patients
Phase 1Terminated
NCT02392312AstellasATF-Fresenius S

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

Start: Jan 2015Est. completion: Mar 2018950 patients
N/ACompleted
NCT01782586GenomicsValidation of Gene Expression Markers of Renal Allograft Functional Decline

Validation of Gene Expression Markers of Renal Allograft Functional Decline

Start: Mar 2013Est. completion: Mar 2018499 patients
N/ACompleted

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
1w ago

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Specialty Account Manager, Nephrology- South Houston, Texas

Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)